A single line often inverts meaning once you see what it
answers, so neighbouring messages are always shown.
-
Francis, We have continued to meet with Mike and his team. One of his team members is coming for a visit in October so we can have a face to face deep dive. a > 8 AM AID) [E] a es ny (NIH/NIAID) Sl > will likely discuss is the Are there any new »f this partnership. Since Sunnylands the Temple group initiated the phase one of a anti-HIV CRISPR trial in Philadelphia, part of the NIAID Collaboratory. We have reviewed a set of grants looking new and improved delivery systems for gene therapies. We plan to fund 3-4 and the details will be announced in the new fiscal year. We are expanding in 2023 the process for sites in LMICs to apply for assistance to support cure trials including but not limited to gene-based technologies. The first iteration of this strategy has been completed, now on to version 2.0. Last, the plans for an bNAb treatment and cure trial in Africa with BMGF is moving forward. Waiting for BMGF to finish production of the bNAbs. This continues to be parallel and complementary activities with BMGF. Best regards, Carl
-
See note from Carl Dieffenbach regarding NIAID activities with BMGF. Thanks, Tony Anthony S. Fauci, MD Director National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 Phone: FAX: E-mail: @niaid.nih.gov The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
-
Thanks, Carl. Is the anti-HIV CRISPR trial targeting CCR5 or integrated proviruses? Francis
-
https://medicine.temple.edu/news/first-clinical-trial-crispr-based-hiv-therapy-founded-breakthrough-research-lewis-katzschool#:~:text=The%20first%20clinical%20trial%20of,investigators%20at%20Excision%20BioTherapeutics%2C%20Inc. Francis The target is HIV. Best regards Carl On Sep 27, 2022, at 5:42 PM, Collins, Francis (NIH/NHGRI) [E] @nih.gov> wrote: Thanks, Carl. Is the anti-HIV CRISPR trial targeting CCR5 or integrated proviruses? Francis
-
2022-09-27 18:52
Francis S. Collins
Cool! That's the kind of protocol I was hoping might work. Let me know what you hear about results. Francis